Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 12/20 | 0.32 |
| ▸ | SLC2A3 | P11169 | 12/20 | 0.32 |
| ▸ | SLC2A4 | P14672 | 12/20 | 0.32 |
| ▸ | SLC2A2 | P11168 | 5/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877765 | 0.94 | SMN1; SMN2 (0.37) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4902450 | 0.85 | HTR2C (0.32) | L3MBTL1HTR2C | |
| SCHEMBL4896675 | 0.83 | TLR7 (0.31) | HTR2C | |
| SCHEMBL4895868 | 0.82 | AOC3 (0.33) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL4901053 | 0.80 | TSHR (0.37) | CYP1A2CYP2C9CYP2C19CYP3A4MEN1 | |
| SCHEMBL14154039 | 0.79 | — | — | |
| SCHEMBL4875978 | 0.79 | KCNH2 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4884136 | 0.77 | SMN1; SMN2 (0.31) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4902928 | 0.76 | TSHR (0.36) | CYP1A2CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL4879792 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | ALDH1A1 84/4885CYP1A2 393/4885CYP2C9 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.